 | Professor of Neurology, Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Director, Stroke Program, Northwestern Memorial Hospital, Chicago, Illinois
Mark J. Alberts, MD, has disclosed the following relevant financial relationships:
Received royalties from: University/Athena Diagnostics for an ApOE genotype test
Received honoraria from: AGA Medical Corporation; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; diaDexus, Inc.; Eli Lilly and Company; Genentech, Inc.; Kos Pharmaceuticals, Inc.; MedscapeCME; Merck & Co., Inc.; Novo Nordisk; PDL BioPharma, Inc.; Pfizer Inc.; sanofi-aventis; Schering-Plough Corporation; TAP Pharmaceutical Products Inc.; The Medicines Company
Received grants for clinical research from: AGA Medical Corporation; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Novo Nordisk; PhotoThera; sanofi-aventis; Schering-Plough Corporation
Served as an advisor or consultant for: AGA Medical Corporation; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc.; Kos Pharmaceuticals, Inc.; MedscapeCME; Merck & Co., Inc.; Novo Nordisk; PDL BioPharma, Inc.; Pfizer Inc.; sanofi-aventis; The Medicines Company
Other: AstraZeneca Pharmaceuticals LP (speaker's bureau); Boehringer Ingelheim Pharmaceuticals, Inc. (speaker's bureau); Bristol-Myers Squibb Company (speaker's bureau); diaDexus, Inc. (speaker's bureau); Genentech, Inc. (speaker's bureau); MedscapeCME (speaker's bureau); Mitsubishi Pharma America, Inc. (review panel); Novo Nordisk (speaker's bureau); PDL BioPharma, Inc. (speaker's bureau); sanofi-aventis (speaker's bureau); Schering-Plough Corporation (review panel); TAP Pharmaceutical Products Inc. (data safety monitoring board); The Medicines Company (speaker's bureau) |
Ischemic Stroke
Stroke Imaging
Middle Cerebral Artery Stroke
AHA Scientific Statement on Rapid Evaluation for Suspected TIA
CV Deaths Jumped in 2020, ReflectingPandemic Toll
Is Preeclampsia a Cardiovascular Time Bomb for Mothers?
COMMENTARY
Aspirin or Anticoagulation? Preventing Cerebral Ischemic Events After Carotid Artery Dissection
Mark J. Alberts, MD
DisclosuresJuly 03, 2009
Georgiadis D, Arnold M, von Buedingen HC, et al. Aspirin vs anticoagulation in carotid artery dissection: a study of 298 patients. Neurology. 2009;72:1810-1815. Available at: https://www.medscape.com/medline/abstract/19321846
Medscape Neurology © 2009 Medscape, LLC
Cite this: Mark J. Alberts. Aspirin or Anticoagulation? Preventing Cerebral Ischemic Events After Carotid Artery Dissection - Medscape - Jul 03, 2009.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Mark J. Alberts, MD
Professor of Neurology, Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Director, Stroke Program, Northwestern Memorial Hospital, Chicago, Illinois
Mark J. Alberts, MD, has disclosed the following relevant financial relationships:
Received royalties from: University/Athena Diagnostics for an ApOE genotype test
Received honoraria from: AGA Medical Corporation; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; diaDexus, Inc.; Eli Lilly and Company; Genentech, Inc.; Kos Pharmaceuticals, Inc.; MedscapeCME; Merck & Co., Inc.; Novo Nordisk; PDL BioPharma, Inc.; Pfizer Inc.; sanofi-aventis; Schering-Plough Corporation; TAP Pharmaceutical Products Inc.; The Medicines Company
Received grants for clinical research from: AGA Medical Corporation; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Novo Nordisk; PhotoThera; sanofi-aventis; Schering-Plough Corporation
Served as an advisor or consultant for: AGA Medical Corporation; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc.; Kos Pharmaceuticals, Inc.; MedscapeCME; Merck & Co., Inc.; Novo Nordisk; PDL BioPharma, Inc.; Pfizer Inc.; sanofi-aventis; The Medicines Company
Other: AstraZeneca Pharmaceuticals LP (speaker's bureau); Boehringer Ingelheim Pharmaceuticals, Inc. (speaker's bureau); Bristol-Myers Squibb Company (speaker's bureau); diaDexus, Inc. (speaker's bureau); Genentech, Inc. (speaker's bureau); MedscapeCME (speaker's bureau); Mitsubishi Pharma America, Inc. (review panel); Novo Nordisk (speaker's bureau); PDL BioPharma, Inc. (speaker's bureau); sanofi-aventis (speaker's bureau); Schering-Plough Corporation (review panel); TAP Pharmaceutical Products Inc. (data safety monitoring board); The Medicines Company (speaker's bureau)